Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Cyclophosphamide 2vocimagene amiretrorepvec 1veliparib 1sacituzumab govitecan 1paclitaxel-Angiopep-2 conjugate 1lenvatinib 1irinotecan sucrosofate 1iniparib 1fludarabine 1depatuxizumab mafodotin 1cabozantinib 1bintrafusp alfa protein, human 1aldesleukin 1Platinum 1Nivolumab 1NVP-BKM120 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Metformin 1Mebendazole 1Ipilimumab 1Interleukin-2 1Flucytosine 1Doxycycline 1Cisplatin 1Capecitabine 1Atorvastatin 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × bintrafusp alfa protein, human × CNS × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡